Form 4: ARS Pharma CMO Sells $700K in Stock

ARS Pharmaceuticals' Chief Medical Officer, Sarina Tanimoto, sold 50,000 shares of common stock for approximately $700,000 through a pre-arranged trading plan.

Summary

• Sarina Tanimoto, Chief Medical Officer and a 10% owner of ARS Pharmaceuticals, Inc. (SPRY), reported the sale of common stock.
• On August 19, 2025, 12,344 shares were sold at a weighted average price of $14.0254 per share, with prices ranging from $14.00 to $14.08.
• On August 20, 2025, an additional 37,656 shares were sold at a weighted average price of $14.0914 per share, with prices ranging from $14.00 to $14.205.
• The total number of shares sold across both transactions was 50,000.
• These sales were executed pursuant to a Rule 10b5-1 trading plan that was entered into on May 15, 2025.
• Following these transactions, Sarina Tanimoto's indirect beneficial ownership through the Sarina Tanimoto Charitable Remainder UniTrust was 1,247,447 shares.
• Additional indirect holdings include 1,246,494 shares through the Richard E. Lowenthal Charitable Remainder UniTrust and 8,859,200 shares through the Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006.

Sentiment

Score: 5

Explanation: The sale is a pre-scheduled transaction under a 10b5-1 plan, which typically indicates personal financial planning rather than a negative view on the company's prospects. However, it is still an insider sale.

Positives

• The stock sales were conducted under a Rule 10b5-1 trading plan, which indicates the transactions were pre-scheduled for personal financial planning purposes rather than being a reaction to new, negative company developments.

Negatives

• The sale of 50,000 shares by a key executive and significant shareholder reduces insider ownership, which can sometimes be perceived negatively by the market, even if pre-planned.

Risks

• No specific risks are detailed in this Form 4 filing beyond the general market perception associated with insider selling, which could be interpreted as a lack of confidence, though mitigated by the 10b5-1 plan.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The reported sales were made from the Sarina Tanimoto Charitable Remainder UniTrust, for which the Reporting Person is a trustee.
• Other indirect holdings are through the Richard E. Lowenthal Charitable Remainder UniTrust (where the Reporting Person's spouse is trustee) and the Lowenthal-Tanimoto Family Trust (where the Reporting Person and spouse are trustees and beneficiaries).

Stakeholder Impact

• Shareholders: A slight reduction in insider ownership, though the pre-planned nature of the sale mitigates concerns about management's immediate outlook on the company.

Key Dates

Recommendation

The filing reports a pre-scheduled insider stock sale by the Chief Medical Officer under a Rule 10b5-1 plan. Such sales are typically for personal financial management and do not necessarily reflect a change in the company's fundamentals or outlook. While it reduces insider ownership, the pre-planned nature suggests it's not a reaction to new negative information. Therefore, it does not warrant a change in investment thesis based solely on this filing.

Keywords

ARS Pharmaceuticals, SPRY, Insider Trading, Form 4, Stock Sale, Sarina Tanimoto, Chief Medical Officer, 10b5-1 Plan